VEGF‐C has wide expression in normal tissues, with measurable mRNA levels in muscle, thyroid, ovary, colon, liver, placenta, and spleen1 and measurable protein levels by immunohistochemistry in breast and prostate.5 It has also been shown to be expressed in various tumor tissues as well, such as thyroid, prostate, gastric, colorectal, lung, and breast.6 VEGF‐C increases tumor metastasis7 and by decreasing VEGF‐C expression in mammary tumors in mice, it was possible to decrease spontaneous metastasis and improve survival.6 Thus, VEGF‐C appears to be an important tumor angiogenic target. The gene discussed is VEGFC; the disease is neoplasm.